RS64429B1 - Čvrsti oblici soli tartarata 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluorpropan-1-ola, proces za njihovu pripremu i postupci za njihovu upotrebu u lečenju kancera - Google Patents

Čvrsti oblici soli tartarata 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluorpropan-1-ola, proces za njihovu pripremu i postupci za njihovu upotrebu u lečenju kancera

Info

Publication number: RS64429B1
Authority: RS; Serbia
Prior art keywords: difluoropropan; fluoropropyl; azetidin; pyrido; indol
Prior art date: 2018-06-21

Application number

RS20230634A

Other languages

English (en)

Inventor

Cheol Keun Chung

Jie Xu

Hans Iding

Kyle Clagg

Michael Dalziel

Alec Fettes

Francis Gosselin

Ngiap-Kie Lim

Andrew Mcclory

Haiming Zhang

Paroma Chakravarty

Kartik Nagapudi

Sarah Robinson

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-06-21

Filing date

2019-06-17

Publication date

2023-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67441580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS64429(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-06-17 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2023-09-29 Publication of RS64429B1 publication Critical patent/RS64429B1/sr

Links

238000000034 method Methods 0.000 title 2
GQCXHIKRWBIQMD-AKJBCIBTSA-N 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol Chemical compound FC1=C(C(=CC(=C1)NC1CN(C1)CCCF)F)[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)CC(CO)(F)F GQCXHIKRWBIQMD-AKJBCIBTSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
239000007787 solid Substances 0.000 title 1
150000003892 tartrate salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Peptides Or Proteins (AREA)

RS20230634A 2018-06-21 2019-06-17 Čvrsti oblici soli tartarata 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluorpropan-1-ola, proces za njihovu pripremu i postupci za njihovu upotrebu u lečenju kancera RS64429B1 (sr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201862687930P	2018-06-21	2018-06-21
US201862719896P	2018-08-20	2018-08-20
EP19745335.0A EP3810283B1 (en)	2018-06-21	2019-06-17	Solid forms of the tartrate salt of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, process for their preparation and methods of their use in treating cancers
PCT/US2019/037492 WO2019245974A1 (en)	2018-06-21	2019-06-17	Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use

Publications (1)

Publication Number	Publication Date
RS64429B1 true RS64429B1 (sr)	2023-09-29

Family

ID=67441580

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20230634A RS64429B1 (sr)	2018-06-21	2019-06-17	Čvrsti oblici soli tartarata 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluorpropan-1-ola, proces za njihovu pripremu i postupci za njihovu upotrebu u lečenju kancera

Country Status (28)

Country	Link
US (4)	US10954234B2 (sr)
EP (2)	EP3810283B1 (sr)
JP (5)	JP6916969B1 (sr)
KR (3)	KR20240113583A (sr)
CN (4)	CN117946107A (sr)
AU (3)	AU2019290545B2 (sr)
CA (1)	CA3098203A1 (sr)
CL (1)	CL2020003022A1 (sr)
CO (1)	CO2020014604A2 (sr)
CR (2)	CR20200621A (sr)
DK (1)	DK3810283T3 (sr)
ES (1)	ES2951829T3 (sr)
FI (1)	FI3810283T3 (sr)
HR (1)	HRP20230859T1 (sr)
HU (1)	HUE064542T2 (sr)
IL (3)	IL278063B2 (sr)
LT (1)	LT3810283T (sr)
MX (3)	MX2020011531A (sr)
PE (1)	PE20211207A1 (sr)
PH (1)	PH12020500676A1 (sr)
PL (1)	PL3810283T3 (sr)
PT (1)	PT3810283T (sr)
RS (1)	RS64429B1 (sr)
SG (1)	SG11202012171SA (sr)
SI (1)	SI3810283T1 (sr)
TW (2)	TWI882617B (sr)
UA (1)	UA128114C2 (sr)
WO (1)	WO2019245974A1 (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS64429B1 (sr) *	2018-06-21	2023-09-29	Hoffmann La Roche	Čvrsti oblici soli tartarata 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluorpropan-1-ola, proces za njihovu pripremu i postupci za njihovu upotrebu u lečenju kancera
EP3993785A4 (en)	2019-07-07	2023-08-02	Olema Pharmaceuticals, Inc.	ESTROGEN RECEPTOR ANTAGONIST SCHEMES
KR20220151616A (ko)	2020-03-06	2022-11-15	올레마 파마슈티컬스 인코포레이티드	에스트로겐 수용체-연관 질환의 치료 방법
WO2021226263A1 (en) *	2020-05-07	2021-11-11	Recurium Ip Holdings, Llc	Combinations
CN115551513B (zh)	2020-05-12	2025-05-02	基因泰克公司	使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
EP4151636A4 (en) *	2020-05-15	2024-02-28	Simcere Pharmaceutical Co. Ltd.	PYRROLIDINE COMPOUND AND ITS USE
US12415799B2 (en)	2020-06-28	2025-09-16	Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	Indazole-fused cyclic compound
TWI861689B (zh) *	2020-06-30	2024-11-11	美商建南德克公司	製備具有經取代之苯基或吡啶基部分的 serd 三環化合物的方法
JP2024502270A (ja)	2020-12-23	2024-01-18	リキュリウムアイピーホールディングスリミテッドライアビリティーカンパニー	エストロゲン受容体調節薬
CN116847839A (zh) *	2021-02-16	2023-10-03	基因泰克公司	使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌
CA3210479A1 (en) *	2021-02-16	2022-08-25	Genentech, Inc.	Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
CN117813288A (zh)	2021-07-15	2024-04-02	西藏海思科制药有限公司	芳氨基衍生物雌激素受体调节剂及其用途
WO2023125700A1 (zh)	2021-12-28	2023-07-06	南京明德新药研发有限公司	四氢环庚吲唑化合物的盐型、晶型
CN114656444A (zh) *	2022-03-04	2022-06-24	河北松辰医药科技有限公司	一种2,2-二氟-1,3-丙基磺酸内酯的合成方法
IL316096A (en)	2022-04-28	2024-12-01	Hoffmann La Roche	Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3 ,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
CN115872996B (zh) *	2023-02-21	2023-05-05	山东绿叶制药有限公司	一种雌激素受体降解剂化合物及其制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7414572L (sr)	1973-12-06	1975-06-09	Endo Lab
SE455604B (sv)	1982-06-29	1988-07-25	Stiftelsen Ind Organisk Elektr	Sett att framstella fenetylaminer medelst elektrokemisk reduktion
DE3639329C1 (de)	1986-11-18	1988-02-25	Heesemann Karl Masch	Bandschleifmaschine
US5023342A (en) *	1988-05-26	1991-06-11	Massachusetts Institute Of Technology	Cyclic sulfate compounds
JP3084578B2 (ja) *	1991-09-11	2000-09-04	興和株式会社	光学活性化合物の製造法
US5206377A (en)	1991-12-05	1993-04-27	Whitby Research, Inc.	Compounds useful as antiproliferative agents
EP0620222A3 (en)	1993-04-14	1995-04-12	Lilly Co Eli	Tetrahydro-beta-carbolines.
RU14873U1 (ru)	2000-06-26	2000-09-10	Закрытое акционерное общество "Патентные услуги"	Комбинированная машина непрерывного литья заготовок
US6987115B2 (en)	2000-12-08	2006-01-17	Smithkline Beecham Corporation	Antibacterial compounds
JP4220779B2 (ja)	2001-02-12	2009-02-04	リリーアイコスリミテッドライアビリティカンパニー	化学化合物
US6951961B2 (en)	2002-05-17	2005-10-04	Marina Nikolaevna Protopopova	Methods of use and compositions for the diagnosis and treatment of infectious disease
TWI329111B (en)	2002-05-24	2010-08-21	X Ceptor Therapeutics Inc	Azepinoindole and pyridoindole derivatives as pharmaceutical agents
ATE482747T1 (de)	2003-04-11	2010-10-15	High Point Pharmaceuticals Llc	Neue amide derivate und deren pharmazeutische verwendungen
EP1670314A4 (en)	2003-09-05	2009-02-25	Sequella Inc	METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS
NZ550365A (en)	2004-03-11	2010-09-30	Actelion Pharmaceuticals Ltd	Tetrahydropyridoindole derivatives
US7767689B2 (en)	2004-03-15	2010-08-03	Ptc Therapeutics, Inc.	Carboline derivatives useful in the treatment of cancer
US8076352B2 (en)	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en)	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Inhibition of VEGF translation
SG184755A1 (en)	2004-03-15	2012-10-30	Ptc Therapeutics Inc	Carboline derivatives useful in the inhibition of angiogenesis
WO2006015035A1 (en)	2004-08-02	2006-02-09	Smithkline Beecham Corporation	Useful compounds for hpv infection
WO2007002051A1 (en)	2005-06-22	2007-01-04	Smithkline Beecham Corporation	Carboline derivatives and their use as inhibitors of flaviviridae infections
WO2007077570A1 (en)	2006-01-02	2007-07-12	Hetero Drugs Limited	Process for obtaining pure oseltamivir
CA2683444A1 (en)	2007-04-13	2008-10-23	Ptc Therapeutics, Inc.	Administration of carboline derivatives useful in the treatment of cancer and other diseases
EP2285808B1 (en)	2008-04-29	2013-11-20	Novartis AG	Spiro-indole derivatives for the treatment of parasitic diseases
US9292307B2 (en)	2008-07-30	2016-03-22	Kyocera Corporation	User interface generation apparatus
WO2010015815A2 (en)	2008-08-05	2010-02-11	Summit Corporation Plc	Compounds for the treatment of flaviviral infections
EP2323652A2 (en)	2008-08-06	2011-05-25	Summit Corporation Plc	Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en)	2008-09-11	2010-03-18	Summit Corporation Plc.	Antiinfective compounds
WO2010049678A2 (en)	2008-10-31	2010-05-06	Summit Corporation Plc	Treatment of energy utilization diseases
WO2010075282A1 (en)	2008-12-22	2010-07-01	University Of Washington	Molecular inhibitors of the wnt/beta-catenin pathway
WO2010075286A1 (en)	2008-12-24	2010-07-01	University Of Washington	MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
DE102009006545B4 (de)	2009-01-29	2017-08-17	Epcos Ag	Überspannungsableiter und Anordnung von mehreren Überspannungsableitern zu einem Array
US20120135089A1 (en)	2009-03-17	2012-05-31	Stockwell Brent R	E3 ligase inhibitors
US8497276B2 (en)	2009-03-31	2013-07-30	Arqule, Inc.	Substituted indolo-piperidine compounds
US20120157402A1 (en)	2009-05-27	2012-06-21	Liangxian Cao	Methods for treating brain tumors
WO2010138685A1 (en)	2009-05-27	2010-12-02	Ptc Therapeutics, Inc.	Methods for treating prostate conditions
WO2010138652A1 (en)	2009-05-27	2010-12-02	Ptc Therapeutics, Inc.	Methods for treating kaposi sarcoma
US20120157401A1 (en)	2009-05-27	2012-06-21	Ptc Therapeutics, Inc.	Methods for treating neurofibromatosis
MX373926B (es)	2009-05-27	2020-07-10	Ptc Therapeutics Inc	Metodos para tratar cancer y estados no neoplasicos.
US20120202801A1 (en)	2009-05-27	2012-08-09	Liangxian Cao	Methods for treating breast cancer
US20130171103A1 (en)	2010-05-27	2013-07-04	Ptc Therapeutics, Inc.	Methods for treating viral conditions
PL2580210T3 (pl)	2010-06-10	2017-09-29	Seragon Pharmaceuticals, Inc.	Modulatory receptora estrogenowego i ich zastosowania
WO2011159769A2 (en)	2010-06-17	2011-12-22	Aragon Pharmaceuticals, Inc.	Indane estrogen receptor modulators and uses thereof
AU2011347718B2 (en)	2010-12-24	2016-06-23	Msd Oss B.V.	N-substituted azetidine derivatives
WO2013090829A1 (en)	2011-12-14	2013-06-20	Aragon Pharmaceuticals, Inc.	Estrogen receptor modulators and uses thereof
CN104508126B (zh)	2012-03-23	2017-06-30	科德克希思公司	用于合成色胺和色胺类似物的衍生物的生物催化剂和方法
WO2013139987A1 (en)	2012-03-23	2013-09-26	Novartis Ag	Chemical process for preparing spiroindolones and intermediates thereof
EP2682119A1 (en)	2012-07-03	2014-01-08	Université Libre de Bruxelles	Aromatic N-heterocycle derivatives for use as medicine
EP2738173A1 (en)	2012-11-28	2014-06-04	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Heterocyclic compounds as inhibitors of the sodium iodide symporter
ME02977B (me)	2013-05-17	2018-10-20	Merck Sharp & Dohme	Fuzionisana triciklicna heterociklicna jedinjenja као inhibiтori hiv integraze
CA2911859A1 (en)	2013-05-28	2014-12-04	Astrazeneca Ab	Chemical compounds
SG11201509508YA (en)	2013-06-19	2015-12-30	Seragon Pharmaceuticals Inc	Estrogen receptor modulator and uses thereof
WO2014205136A1 (en)	2013-06-19	2014-12-24	Seragon Pharmaceuticals, Inc.	Azetidine estrogen receptor modulators and uses thereof
WO2015039348A1 (en)	2013-09-23	2015-03-26	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
KR102266696B1 (ko)	2013-10-28	2021-06-21	드렉셀유니버시티	주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제
US9675586B2 (en)	2013-12-06	2017-06-13	Genentech, Inc.	Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
RU2016137150A (ru)	2014-03-13	2018-04-18	Ф. Хоффманн-Ля Рош Аг	Способы и композиции для модулирования мутантов эстрогеновых рецепторов
MA39741A (fr)	2014-03-13	2017-01-18	Hoffmann La Roche	Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
MX388871B (es)	2014-06-27	2025-03-20	Nogra Pharma Ltd	Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
JP6807841B2 (ja)	2014-12-18	2021-01-06	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	エストロゲン受容体モジュレーター及びその使用
CN107406433A (zh)	2014-12-18	2017-11-28	豪夫迈·罗氏有限公司	用于治疗癌症的2,3‑二苯基色烯的衍生物
CN117865872A (zh) *	2014-12-18	2024-04-12	豪夫迈·罗氏有限公司	四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US10292971B2 (en)	2015-10-01	2019-05-21	Olema Pharmaceuticals, Inc.	Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs
CN113788826B (zh) *	2016-02-01	2025-08-01	武田药品工业株式会社	共晶体
AU2017213614B2 (en)	2016-02-05	2022-09-01	Inventisbio Llc	Selective estrogen receptor degraders and uses thereof
EP3472159A1 (en)	2016-06-16	2019-04-24	F. Hoffmann-La Roche AG	TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3472162B1 (en) *	2016-06-16	2021-11-17	F. Hoffmann-La Roche AG	Heteroaryl estrogen receptor modulators and uses thereof
RS64429B1 (sr)	2018-06-21	2023-09-29	Hoffmann La Roche	Čvrsti oblici soli tartarata 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluorpropan-1-ola, proces za njihovu pripremu i postupci za njihovu upotrebu u lečenju kancera

2019
- 2019-06-17 RS RS20230634A patent/RS64429B1/sr unknown
- 2019-06-17 IL IL278063A patent/IL278063B2/en unknown
- 2019-06-17 UA UAA202100182A patent/UA128114C2/uk unknown
- 2019-06-17 AU AU2019290545A patent/AU2019290545B2/en active Active
- 2019-06-17 KR KR1020247022192A patent/KR20240113583A/ko active Pending
- 2019-06-17 LT LTEPPCT/US2019/037492T patent/LT3810283T/lt unknown
- 2019-06-17 PE PE2020001888A patent/PE20211207A1/es unknown
- 2019-06-17 CN CN202410165649.2A patent/CN117946107A/zh active Pending
- 2019-06-17 IL IL319760A patent/IL319760A/en unknown
- 2019-06-17 PL PL19745335.0T patent/PL3810283T3/pl unknown
- 2019-06-17 CA CA3098203A patent/CA3098203A1/en active Pending
- 2019-06-17 ES ES19745335T patent/ES2951829T3/es active Active
- 2019-06-17 CN CN202410165685.9A patent/CN118515596A/zh active Pending
- 2019-06-17 HU HUE19745335A patent/HUE064542T2/hu unknown
- 2019-06-17 CN CN201980041221.4A patent/CN112437685B/zh active Active
- 2019-06-17 SG SG11202012171SA patent/SG11202012171SA/en unknown
- 2019-06-17 US US16/443,515 patent/US10954234B2/en active Active
- 2019-06-17 EP EP19745335.0A patent/EP3810283B1/en active Active
- 2019-06-17 JP JP2020570698A patent/JP6916969B1/ja active Active
- 2019-06-17 SI SI201930592T patent/SI3810283T1/sl unknown
- 2019-06-17 MX MX2020011531A patent/MX2020011531A/es unknown
- 2019-06-17 CN CN202410165668.5A patent/CN118239948A/zh active Pending
- 2019-06-17 WO PCT/US2019/037492 patent/WO2019245974A1/en not_active Ceased
- 2019-06-17 KR KR1020217001924A patent/KR102564647B1/ko active Active
- 2019-06-17 KR KR1020237026161A patent/KR102682985B1/ko active Active
- 2019-06-17 FI FIEP19745335.0T patent/FI3810283T3/fi active
- 2019-06-17 CR CR20200621A patent/CR20200621A/es unknown
- 2019-06-17 DK DK19745335.0T patent/DK3810283T3/da active
- 2019-06-17 HR HRP20230859TT patent/HRP20230859T1/hr unknown
- 2019-06-17 CR CR20230409A patent/CR20230409A/es unknown
- 2019-06-17 PT PT197453350T patent/PT3810283T/pt unknown
- 2019-06-17 EP EP23178559.3A patent/EP4295845A3/en active Pending
- 2019-06-17 TW TW112151443A patent/TWI882617B/zh active
- 2019-06-17 TW TW108120952A patent/TWI846704B/zh active
- 2019-06-17 IL IL319761A patent/IL319761A/en unknown
2020
- 2020-10-29 MX MX2023006785A patent/MX2023006785A/es unknown
- 2020-10-29 MX MX2022016065A patent/MX2022016065A/es unknown
- 2020-11-20 CL CL2020003022A patent/CL2020003022A1/es unknown
- 2020-11-25 CO CONC2020/0014604A patent/CO2020014604A2/es unknown
- 2020-12-03 US US17/110,607 patent/US11780834B2/en active Active
- 2020-12-17 PH PH12020500676A patent/PH12020500676A1/en unknown
2021
- 2021-07-16 JP JP2021117638A patent/JP2021191751A/ja active Pending
- 2021-07-16 JP JP2021117633A patent/JP7660040B2/ja active Active
2022
- 2022-05-03 AU AU2022202967A patent/AU2022202967B2/en active Active
2023
- 2023-08-25 US US18/455,783 patent/US20240317738A1/en active Pending
- 2023-09-13 AU AU2023229513A patent/AU2023229513A1/en active Pending
2024
- 2024-01-11 JP JP2024002374A patent/JP2024054111A/ja active Pending
- 2024-05-02 US US18/652,953 patent/US20240409535A1/en active Pending
- 2024-07-19 JP JP2024115623A patent/JP2024164006A/ja active Pending

Also Published As

Publication number	Publication date
KR102564647B1 (ko)	2023-08-11
US20200002331A1 (en)	2020-01-02
IL278063A (en)	2020-11-30
US20220041587A1 (en)	2022-02-10
AU2022202967A1 (en)	2022-05-26
ES2951829T3 (es)	2023-10-25
TW202016098A (zh)	2020-05-01
US20240409535A1 (en)	2024-12-12
CN117946107A (zh)	2024-04-30
PL3810283T3 (pl)	2023-10-16
JP2024164006A (ja)	2024-11-26
EP3810283A1 (en)	2021-04-28
MX2022016065A (es)	2023-02-02
CN112437685B (zh)	2024-08-09
KR102682985B1 (ko)	2024-07-10
JP2024054111A (ja)	2024-04-16
AU2019290545B2 (en)	2022-04-14
FI3810283T3 (fi)	2023-08-11
SG11202012171SA (en)	2021-01-28
TW202440552A (zh)	2024-10-16
BR112020024073A2 (pt)	2021-02-17
US10954234B2 (en)	2021-03-23
CN118515596A (zh)	2024-08-20
IL278063B2 (en)	2025-08-01
WO2019245974A8 (en)	2020-11-05
PH12020500676A1 (en)	2021-06-14
PE20211207A1 (es)	2021-07-05
TWI846704B (zh)	2024-07-01
KR20210022701A (ko)	2021-03-03
HUE064542T2 (hu)	2024-03-28
US11780834B2 (en)	2023-10-10
CN112437685A (zh)	2021-03-02
AU2022202967B2 (en)	2024-02-22
EP4295845A3 (en)	2024-02-28
JP2021522312A (ja)	2021-08-30
UA128114C2 (uk)	2024-04-10
CO2020014604A2 (es)	2020-12-10
AU2023229513A1 (en)	2023-10-05
IL278063B1 (en)	2025-04-01
WO2019245974A1 (en)	2019-12-26
CL2020003022A1 (es)	2021-06-04
PT3810283T (pt)	2023-08-18
LT3810283T (lt)	2023-08-25
SI3810283T1 (sl)	2023-10-30
DK3810283T3 (en)	2023-08-21
EP4295845A2 (en)	2023-12-27
CR20230409A (es)	2023-09-25
HRP20230859T1 (hr)	2023-11-10
JP7660040B2 (ja)	2025-04-10
TWI882617B (zh)	2025-05-01
JP2021191750A (ja)	2021-12-16
KR20240113583A (ko)	2024-07-22
AU2019290545A1 (en)	2020-11-19
US20240317738A1 (en)	2024-09-26
CA3098203A1 (en)	2019-12-26
CN118239948A (zh)	2024-06-25
MX2023006785A (es)	2023-06-20
JP2021191751A (ja)	2021-12-16
EP3810283B1 (en)	2023-06-14
CR20200621A (es)	2021-02-03
IL319760A (en)	2025-05-01
KR20230117761A (ko)	2023-08-09
IL319761A (en)	2025-05-01
MX2020011531A (es)	2021-03-25
JP6916969B1 (ja)	2021-08-11

Publication	Publication Date	Title
RS64429B1 (sr)	2023-09-29	Čvrsti oblici soli tartarata 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluorpropan-1-ola, proces za njihovu pripremu i postupci za njihovu upotrebu u lečenju kancera
WO2020176597A9 (en)	2021-08-05	N-substituted indoles and other heterocycles for treating brain disorders
HUE055339T2 (hu)	2021-11-29	Új L-triptofán-exportfehérje és eljárás L-triptofán elõállítására annak alkalmazásával
GB201212081D0 (en)	2012-08-22	New polymorph
MX354373B (es)	2018-02-28	Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales.
WO2018237379A3 (en)	2019-02-07	COMPOUNDS MODULATING THE PATH OF SPHINGOSINE FOR THE TREATMENT OF CANCERS
IL312413B1 (en)	2025-09-01	Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-enol)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
EA201401027A1 (ru)	2015-03-31	НОВЫЕ КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ ГЕМИНАПАДИЗИЛАТА 5-(2-{[6-(2,2-ДИФТОР-2-ФЕНИЛЭТОКСИ)ГЕКСИЛ]АМИНО}-1-(R)-ГИДРОКСИЭТИЛ)-8-ГИДРОКСИХИНОЛИН-2(1H)-ОНА В КАЧЕСТВЕ АГОНИСТОВ βАДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
ZA202002957B (en)	2025-04-30	Fumarate salt of (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof
IL289198A (en)	2022-02-01	Solid forms of tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-5,2-diazaspiro[4.3]octane- 5-carboxylate and methods for their preparation
WO2018098292A3 (en)	2018-07-26	Methods for treating opioid addiction
WO2017214249A3 (en)	2018-01-18	Gm-csf variants and methods of use
PL3655395T3 (pl)	2022-03-07	Proces otrzymywania n-((1r,2s,sr)-5-(tert-butyloamino)-2-((s)-3-(7-tert-butylopirazolo[1,5-a][1,3,5]triazyn-4-yloamino)-2-oksopirolidyn-1-ylo)cykloheksylo)acetamidu
IL316096A (en)	2024-12-01	Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3 ,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
AR114974A1 (es)	2020-11-11	Procesos para preparar compuestos tricíclicos fusionados que comprenden un resto piridinilo o fenilo sustituido, incluidos métodos para su uso
HK40115442A (en)	2025-03-28	Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
IL308121A (en)	2023-12-01	Treatment methods with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1 - oxoisoindoline-5-carboxamide
HK40066602A (en)	2022-08-19	N-substituted indoles and other heterocycles for treating brain disorders
WO2016112382A3 (en)	2016-09-29	Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors
WO2020159041A9 (ko)	2020-09-24	미립자 공정을 통해 분산된 파우더 조성물의 제조방법 및 이를 통해 제조된 파우더 조성물
EP3886891C0 (en)	2024-11-20	LAMININ RECEPTOR PRECURSOR/ HIGH AFFINITY LAMININ RECEPTOR (LRP/LR) FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
HK40112723A (en)	2025-01-24	Use of polyamines in the treatment of brain tumours
HK40055116A (en)	2022-03-04	Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
WO2016164476A3 (en)	2016-12-01	Combination of an acat1 inhibitor and a cyp1 1 b1 inhibitor for treating disorders associated with excess cortisol production
HK1153734A (en)	2012-04-05	Compounds and methods of use